Activating the innate and adaptive immune system to recognize and attack tumors
A large number of cancers will respond to PD-1/PD-L1 checkpoint inhibitors; however, for patients with tumors that do not already express PD-L1, response to approved agents is often limited or minimal. Portage’s small molecule invariant natural killer T cell (iNKT) engagers may be able to activate the immune response in these patients to effectively identify and target the tumor.
Our iNKT engagers, PORT-2 and PORT-3, lead to a broad reprogramming of the innate and adaptive immune system, enabling the body to recognize and attack tumors that contain few immune cells and usually go undetected. Both PORT-2 and PORT-3 may be used alone or in combination with checkpoint inhibitors, potentially helping more patients respond to treatment.